Jaguar Health, Inc. (JAGX) Form 424B3 — Nov 9, 2026
Jaguar Health filed a 424B3 base prospectus registering up to $75,000,000 of common stock, preferred stock, warrants, subscription rights, and units for sale from time to time off its Form S-3 shelf. No securities are being sold in this filing itself; each future takedown will require its own prospectus supplement. The filing comes with the stock at $0.8841 (Nov 2, 2026) and only ~13.3 million shares outstanding after the Series R preferred converted 5-for-1 on November 2, 2026. A full $75M shelf takedown against that share count would represent extreme potential dilution.
Key figures
- Gross Proceeds
- 75000000
- Offering Price
- 0.8841
- Shares Outstanding
- 13345986
- Share price as of
- 2026-11-02
- Future pak upfront capital
- 16000000
- Future pak milestones potential
- 20000000
- Shares of series r converted 5 to 1
- 2188712
- Streeterville 2025 note original principal
- 10810000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.